Close Menu

equity investment

The new Series B investment was made by Northpond Ventures, with previously invested $20 million in the Australian diagnostics company.

Uppsala University spinout Astrego has developed a system to rapidly detect bacterial infection and antibiotic susceptibility in biofluid.

The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.

Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.

The Australian molecular diagnostics firm will use the funds to accelerate commercial expansion in North America and global markets.

Denka now owns 33.4 percent of PlexBio's shares. PlexBio will use the financing for operations and product development.

The financing will go toward ongoing commercialization of the firm's autoimmune tests and therapeutics promotion business.

Variantyx, a 2014 spinout from Tel Aviv University that is based in Framingham, Massachusetts, provides clinical genomic testing for screening and rare disease diagnostics.

BioMérieux has increased its stake in Chinese immunoassay developer Hybiome Biomedical Engineering from 54 percent to 67 percent.

The new funding brings the Series B total to £23.3 million for the British clinical decision support technology developer.

Pages